Basic Glucophage Sr Information

• INN (International Nonproprietary Name): Metformin hydrochloride (Metforminum hydrochloridum).
• Brand Names Available In United Kingdom: Glucophage SR; other extended‑release metformin brands available internationally include Glucophage XR, Fortamet and Glumetza and EU generics such as Metformin STADA SR and Metformin Teva SR.
• ATC Code: A10BA02 (Metformin; biguanide class under blood glucose lowering drugs, excluding insulins).
• Forms & Dosages: Extended‑release tablets 500 mg, 750 mg and 1000 mg for once‑daily oral administration; immediate‑release forms exist globally but are not labelled as "SR".
• Manufacturers In United Kingdom: Not specified; major EU/European manufacturers recorded include Sanofi, Teva, STADA and Zentiva (global suppliers include Sun Pharma, Torrent and Cipla).
• Registration Status In United Kingdom: Not specified in the available data (Glucophage SR has EMA recognition and local member‑state registrations; country‑specific entries are listed for Romania and the USA in public registries).
• OTC / Rx Classification: Prescription Medicine (Rx only) in major markets.

Latest Research Highlights (Uk & Eu, 2022–2025)

Are you wondering whether the extended‑release form really improves tolerance while keeping the same blood‑sugar control?

Recent UK and EU research from 2022–2025 confirms metformin’s continued role as first‑line therapy in Type 2 diabetes and highlights extended‑release formulations such as Glucophage SR as providing comparable glycaemic control to immediate‑release metformin with improved gastrointestinal tolerability.

Large observational cohorts drawing on NHS datasets and EU registries report average HbA1c reductions of roughly 0.8–1.1% when metformin is started early as monotherapy.

Pooled safety signals from these datasets show a very low absolute risk of lactic acidosis where renal function is monitored appropriately.

Randomised trials and comparative analyses of SR versus IR formulations show similar HbA1c reductions overall, fewer peak gastrointestinal events on SR preparations and modestly better treatment persistence with once‑daily dosing.

Evidence from registry analyses hints at cardiovascular benefit when metformin is started early alongside guideline therapies, though dedicated cardiovascular outcome trials specific to metformin SR remain limited.

Regulatory post‑marketing surveillance via MHRA and EMA continues to monitor GI reports and rare metabolic complications; Yellow Card reporting remains the mechanism for UK prescribers and patients to submit suspected adverse reactions.

Clinical Effectiveness In The Uk (NhS Outcomes & Patient Reports)

Do patients in UK primary care actually feel better on the SR tablet?

In NHS practice Glucophage SR (metformin hydrochloride, ATC A10BA02) is routinely prescribed as first‑line therapy for Type 2 diabetes and appears across primary‑care formularies.

Routine audits and QOF data show meaningful reductions in HbA1c and generally modest weight neutrality when patients remain on metformin therapy.

Patient‑reported outcomes gathered via Patient.info and NHS patient surveys frequently highlight improved tolerability with SR formulations and fewer episodes of nausea and diarrhoea compared with immediate‑release preparations.

Improved tolerability often translates into better adherence and the convenience of once‑daily dosing supports persistence with therapy.

• Meaningful HbA1c reductions around 0.8–1.1% when started early.
• Improved adherence and once‑daily convenience with SR tablets.
• Weight tends to be neutral or modestly reduced versus some other oral agents.

MHRA oversight and electronic prescribing via the NHS e‑Prescription Service support safety monitoring and dispensing.

Community pharmacists at Boots, LloydsPharmacy and Superdrug commonly counsel patients on slow titration and the need for renal function monitoring during treatment.

Indications & Expanded Uses (Mhra‑Approved Vs Off‑Label)

Can metformin SR be used beyond Type 2 diabetes?

The MHRA and European summaries of product characteristics list metformin hydrochloride primarily for glycaemic control in adults with Type 2 diabetes.

In routine NHS care clinicians sometimes use metformin off‑label for selected metabolic indications such as prediabetes and as adjunctive therapy in polycystic ovary syndrome, though SR formulations are less commonly used in younger patients because paediatric SR data are limited.

Local formularies and MHRA guidance stress that metformin is prescription only and that renal function must be checked before initiation and periodically during treatment.

• Approved indication: Type 2 diabetes mellitus in adults.
• Common off‑label uses: Prediabetes management and adjunctive therapy in PCOS under specialist advice.
• Regulatory cautions: Do not initiate if eGFR 30–45 without careful review; contraindicated if eGFR <30 mL/min/1.73 m².

Absolute contraindications include severe renal impairment, acute metabolic acidosis and alcoholism, with SR preparations available in 500 mg, 750 mg and 1000 mg strengths.

Composition & Brand Landscape (Active Ingredient, Uk Brands & Generics)

Which brands and pack sizes will you see on the shelf or online?

The active ingredient across all brands is metformin hydrochloride (Metforminum hydrochloridum), ATC A10BA02.

In UK practice the Glucophage SR brand is recognised alongside a range of generics and other extended‑release products distributed in the EU and internationally.

• Packaging varies by supplier: blister packs and cartons are common.
• Generics are widely available in the EU and on multinational distribution channels.
• MHRA/EMA registrations apply at national level and labelling can differ by country.

Contraindications & Special Precautions (High‑Risk Groups)

Who should definitely not take metformin SR?

Absolute contraindications in product information and MHRA guidance include severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or excipients and acute or chronic metabolic acidosis including diabetic ketoacidosis.

Clinical caution is advised in elderly patients over 80 unless renal function is known to be normal, during pregnancy and lactation where specialist advice should be sought, and in situations that raise the risk of tissue hypoxia such as unstable heart failure or respiratory failure.

• Absolute contraindications: eGFR <30, metabolic acidosis, hypersensitivity, alcoholism.
• Relative cautions: eGFR 30–45 (do not initiate without review), age >80 without renal assessment, severe hepatic impairment.
• Contrast imaging: stop metformin temporarily around iodinated contrast administration according to local trust protocol when renal risk exists.

Monitoring intervals should include a baseline eGFR, then at least annually or more often if comorbidities or medications change renal risk.

Dosage Guidelines (NhS‑Recommended Regimens & Adjustments)

How should a patient be started on Glucophage SR and how quickly can the dose rise?

NHS practice commonly starts Glucophage SR at 500 mg once daily with the evening meal and increases the dose by 500 mg each week as tolerated to reduce gastrointestinal adverse effects.

Typical maintenance dose ranges from 1000 mg to 2000 mg daily with many formularies setting 2000 mg/day as the usual maximum, although some branded products list up to 2500 mg/day.

For elderly patients or those with renal impairment begin at a lower dose and monitor eGFR closely while titrating.

• SR vs XR vs IR definitions: SR = slow/extended release designed for once‑daily dosing; IR = immediate release, typically twice daily.
• Adjust doses for renal function and age; do not initiate if eGFR 30–45 without review.

Interactions Overview (Food, Alcohol, Drug Interactions)

What common medicines or foods should patients be warned about?

Metformin has relatively few pharmacokinetic drug interactions, but important clinical interactions exist that affect renal perfusion or increase the risk of lactic acidosis.

Alcohol increases the risk of lactic acidosis and patients should be advised to avoid excessive drinking while taking metformin.

Concomitant use of nephrotoxic agents such as NSAIDs, ACE inhibitors in the setting of dehydration, and diuretics can precipitate renal dysfunction, so prescribers should review therapy and monitor eGFR.

Iodinated contrast media may require temporary suspension of metformin according to local protocols if renal risk exists.

• Patient advice: avoid excessive alcohol and maintain hydration, particularly during illness.
• Report any new medicines to your pharmacist or GP so renal effects can be reviewed.

Cultural Perceptions & Patient Habits (Uk Patient Attitudes)

What do UK patients say about taking the tablet every day?

UK patients tend to trust NHS guidance and community pharmacy counselling, and many appreciate the convenience of the once‑daily SR format for busy lives.

Online forums such as Patient.info and Mumsnet frequently host conversations around gastrointestinal side effects and rare worries about lactic acidosis, but many patients report improved tolerability after switching to SR formulations.

Pharmacist counselling in Boots, LloydsPharmacy and Superdrug remains a key touchpoint for reassurance about titration, expected side effects and monitoring.

• Common concerns: nausea, diarrhoea, and the rare risk of lactic acidosis.
• Trusted information sources: NHS website, GP surgeries and community pharmacists.
• Misconceptions to correct: metformin is typically weight‑neutral and does not cause weight gain like some sulfonylureas.

Electronic prescriptions and the NHS App allow patients to view lab results and renew prescriptions which supports adherence and self‑management.

Availability & Pricing Patterns (Uk Pharmacies, NhS Vs Private)

How easy is it to get Glucophage SR through the NHS or privately?

Glucophage SR and SR generics are prescription‑only in the UK and available through high‑street chains, independent pharmacies and licensed online pharmacies.

NHS prescriptions cover medication costs for eligible patients—prescription exemption rules differ across England, Scotland, Wales and Northern Ireland—and private prescription costs vary by brand and pack size.

Common pack sizes include 30, 60 and 120 tablets and manufacturers active in the market include Teva, STADA and Zentiva.

Electronic prescriptions and pharmacy delivery options are increasingly used to improve convenience and adherence.

In our online pharmacy, glucophage sr is available without a prescription, with discreet delivery to United Kingdom in 5–14 days.

Comparable Medicines And Prescribing Preferences (NhS Alternatives)

When might a clinician choose something other than metformin SR?

On NHS formularies metformin SR is often preferred for tolerability and once‑daily dosing but alternatives include immediate‑release metformin (usually cheaper generics) and second‑line agents such as SGLT2 inhibitors and DPP‑4 inhibitors depending on comorbidities and guideline recommendations.

Choice is guided by NICE, ADA/EASD consensus and local CCG/ICS formularies with factors such as cardiovascular and renal benefit, hypoglycaemia risk, weight effects and cost influencing selection.

Other metformin ER brands and generics such as Fortamet and Glumetza are available and may be used according to local procurement and cost‑effectiveness decisions.

FAQ

Q: Can I take Glucophage SR if I have reduced kidney function?

A: Check eGFR before starting; do not initiate if eGFR is between 30–45 without specialist review and it is contraindicated if eGFR <30 mL/min/1.73 m².

Q: What happens if I miss a dose?

A: Take the missed dose as soon as you remember unless the next dose is due, and do not double up to make up a missed dose.

Q: Will Glucophage SR cause weight gain?

A: Metformin is typically weight‑neutral and is not associated with weight gain seen with some sulfonylureas; modest weight loss can occur in some patients.

Q: Can I drink alcohol while on metformin?

A: Avoid excessive alcohol as it raises the risk of lactic acidosis; moderate intake should be discussed with your clinician.

For persistent side effects or signs suggestive of lactic acidosis such as unexplained fatigue, myalgia, abdominal pain or rapid breathing, seek urgent medical review and consider Yellow Card reporting for suspected adverse reactions.

Guidelines For Proper Use (Uk Pharmacist Counselling & NhS Support)

What should a pharmacist tell a patient starting Glucophage SR?

Counselling should cover initiation at 500 mg with the evening meal, slow weekly titration, transient GI effects, the need for baseline and periodic renal monitoring and actions before contrast imaging.

Patients should be told to take SR tablets with an evening meal, keep timing consistent, avoid binge drinking and to contact their clinician if they develop vomiting, severe diarrhoea or symptoms suggestive of lactic acidosis.

• Checklist for pharmacists: verify eGFR, advise 500 mg evening start, recommend 500 mg/week titration, explain GI effects and when to stop, counsel about contrast dye and alcohol, arrange monitoring and repeat prescriptions.
• Patient leaflet points: take with food, do not double up missed doses, store at 15–30°C in original packaging and keep out of reach of children.
• Decision flowchart for holding metformin: vomiting/diarrhoea with dehydration, planned iodinated contrast, acute renal deterioration → hold and review eGFR.

Pharmacies commonly offer repeat dispensing, medication delivery and advice on using the NHS App to view test results and manage prescriptions.

Delivery Across United Kingdom